ES2559183T3 - Procedimientos de tratamiento de una enfermedad de tipo inflamatorio - Google Patents

Info

Publication number

ES2559183T3

ES2559183T3 ES11157590.8T ES11157590T ES2559183T3 ES 2559183 T3 ES2559183 T3 ES 2559183T3 ES 11157590 T ES11157590 T ES 11157590T ES 2559183 T3 ES2559183 T3 ES 2559183T3

Authority

ES

Spain

Prior art keywords

group

inflammatory

substituted

compound

disease

Prior art date

2004-01-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Lifetime

Links

• Espacenet
• Global Dossier
• Discuss

• 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 51
• 238000000034 method Methods 0.000 title description 47
• 108090000695 Cytokines Proteins 0.000 claims abstract description 156
• 102000004127 Cytokines Human genes 0.000 claims abstract description 155
• 238000011282 treatment Methods 0.000 claims abstract description 81
• 150000001875 compounds Chemical class 0.000 claims abstract description 65
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 51
• 230000014509 gene expression Effects 0.000 claims abstract description 48
• 201000010099 disease Diseases 0.000 claims abstract description 46
• -1 nitroxy moieties Chemical group 0.000 claims abstract description 39
• 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 38
• 230000002757 inflammatory effect Effects 0.000 claims abstract description 33
• 150000002772 monosaccharides Chemical class 0.000 claims abstract description 24
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 21
• 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 19
• 125000003118 aryl group Chemical group 0.000 claims abstract description 14
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 14
• 206010009887 colitis Diseases 0.000 claims abstract description 13
• 150000001408 amides Chemical class 0.000 claims abstract description 12
• 150000001413 amino acids Chemical class 0.000 claims abstract description 12
• 229910052736 halogen Inorganic materials 0.000 claims abstract description 12
• 150000002367 halogens Chemical class 0.000 claims abstract description 12
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
• 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
• 150000001412 amines Chemical class 0.000 claims abstract description 10
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 9
• 125000005842 heteroatom Chemical group 0.000 claims abstract description 9
• 150000002016 disaccharides Chemical class 0.000 claims abstract description 8
• 229940124530 sulfonamide Drugs 0.000 claims abstract description 8
• 150000003456 sulfonamides Chemical class 0.000 claims abstract description 8
• 125000005843 halogen group Chemical group 0.000 claims abstract description 7
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 7
• 150000003467 sulfuric acid derivatives Chemical class 0.000 claims abstract description 7
• 125000002252 acyl group Chemical group 0.000 claims abstract description 6
• 235000000346 sugar Nutrition 0.000 claims abstract description 6
• 150000003573 thiols Chemical class 0.000 claims abstract description 6
• 208000015943 Coeliac disease Diseases 0.000 claims abstract description 5
• 206010010744 Conjunctivitis allergic Diseases 0.000 claims abstract description 5
• 208000021386 Sjogren Syndrome Diseases 0.000 claims abstract description 5
• 206010046851 Uveitis Diseases 0.000 claims abstract description 5
• 208000002205 allergic conjunctivitis Diseases 0.000 claims abstract description 5
• 208000024998 atopic conjunctivitis Diseases 0.000 claims abstract description 5
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 5
• 239000003270 steroid hormone Substances 0.000 claims abstract description 5
• 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 4
• 125000003277 amino group Chemical group 0.000 claims abstract description 3
• 125000000751 azo group Chemical group [*]N=N[*] 0.000 claims abstract description 3
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract description 3
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 3
• GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims abstract description 3
• 229920001542 oligosaccharide Polymers 0.000 claims abstract description 3
• 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 3
• 239000000813 peptide hormone Substances 0.000 claims abstract description 3
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 3
• 150000008163 sugars Chemical class 0.000 claims abstract description 3
• 125000004665 trialkylsilyl group Chemical group 0.000 claims abstract description 3
• 125000005106 triarylsilyl group Chemical group 0.000 claims abstract description 3
• 125000000539 amino acid group Chemical group 0.000 claims abstract 2
• 102100040247 Tumor necrosis factor Human genes 0.000 claims description 67
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 66
• 108090001005 Interleukin-6 Proteins 0.000 claims description 65
• 102000004889 Interleukin-6 Human genes 0.000 claims description 64
• 239000003814 drug Substances 0.000 claims description 44
• 108090000174 Interleukin-10 Proteins 0.000 claims description 41
• 102000003814 Interleukin-10 Human genes 0.000 claims description 40
• 241001465754 Metazoa Species 0.000 claims description 40
• 239000000203 mixture Substances 0.000 claims description 29
• 239000003795 chemical substances by application Substances 0.000 claims description 26
• 238000004519 manufacturing process Methods 0.000 claims description 26
• 238000002360 preparation method Methods 0.000 claims description 18
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
• 108010002350 Interleukin-2 Proteins 0.000 claims description 12
• 102000000588 Interleukin-2 Human genes 0.000 claims description 12
• 239000011734 sodium Substances 0.000 claims description 12
• 229910052708 sodium Inorganic materials 0.000 claims description 12
• 229940083542 sodium Drugs 0.000 claims description 11
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 10
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 10
• 102000013462 Interleukin-12 Human genes 0.000 claims description 9
• 108010065805 Interleukin-12 Proteins 0.000 claims description 9
• 239000003435 antirheumatic agent Substances 0.000 claims description 9
• 108050003558 Interleukin-17 Proteins 0.000 claims description 6
• 102000013691 Interleukin-17 Human genes 0.000 claims description 6
• 108010002386 Interleukin-3 Proteins 0.000 claims description 6
• 102000000646 Interleukin-3 Human genes 0.000 claims description 6
• 108010002586 Interleukin-7 Proteins 0.000 claims description 6
• 102000000704 Interleukin-7 Human genes 0.000 claims description 6
• 108010002335 Interleukin-9 Proteins 0.000 claims description 6
• 102000000585 Interleukin-9 Human genes 0.000 claims description 6
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
• 210000004400 mucous membrane Anatomy 0.000 claims description 6
• 108090000177 Interleukin-11 Proteins 0.000 claims description 5
• 102000003815 Interleukin-11 Human genes 0.000 claims description 5
• 102000004388 Interleukin-4 Human genes 0.000 claims description 5
• 108090000978 Interleukin-4 Proteins 0.000 claims description 5
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 5
• 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 5
• 201000005569 Gout Diseases 0.000 claims description 4
• 102000003810 Interleukin-18 Human genes 0.000 claims description 4
• 108090000171 Interleukin-18 Proteins 0.000 claims description 4
• 230000000202 analgesic effect Effects 0.000 claims description 4
• 229960003957 dexamethasone Drugs 0.000 claims description 4
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
• 239000004083 gastrointestinal agent Substances 0.000 claims description 4
• 229940125695 gastrointestinal agent Drugs 0.000 claims description 4
• 239000003862 glucocorticoid Substances 0.000 claims description 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
• BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims description 4
• 229960004384 ketorolac tromethamine Drugs 0.000 claims description 4
• 230000000241 respiratory effect Effects 0.000 claims description 4
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
• 108010036949 Cyclosporine Proteins 0.000 claims description 3
• 229960001265 ciclosporin Drugs 0.000 claims description 3
• 229930182912 cyclosporin Natural products 0.000 claims description 3
• 229960000890 hydrocortisone Drugs 0.000 claims description 3
• 229960004963 mesalazine Drugs 0.000 claims description 3
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 2
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
• POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 claims description 2
• BGSOJVFOEQLVMH-UHFFFAOYSA-N Hydrocortisone phosphate Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)COP(O)(O)=O)C4C3CCC2=C1 BGSOJVFOEQLVMH-UHFFFAOYSA-N 0.000 claims description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
• ZJEFYLVGGFISGT-VRZXRVJBSA-L [Na+].[Na+].Oc1ccc(cc1C([O-])=O)\N=N\c1ccc(O)c(c1)C([O-])=O Chemical compound [Na+].[Na+].Oc1ccc(cc1C([O-])=O)\N=N\c1ccc(O)c(c1)C([O-])=O ZJEFYLVGGFISGT-VRZXRVJBSA-L 0.000 claims description 2
• XDCNKOBSQURQOZ-MVIJUDHYSA-L balsalazide disodium Chemical compound O.O.[Na+].[Na+].C1=C(C([O-])=O)C(O)=CC=C1\N=N\C1=CC=C(C(=O)NCCC([O-])=O)C=C1 XDCNKOBSQURQOZ-MVIJUDHYSA-L 0.000 claims description 2
• 229940038482 beclomethasone dipropionate monohydrate Drugs 0.000 claims description 2
• 229960004311 betamethasone valerate Drugs 0.000 claims description 2
• SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 2
• 229960004436 budesonide Drugs 0.000 claims description 2
• 229960001231 choline Drugs 0.000 claims description 2
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
• 229960004703 clobetasol propionate Drugs 0.000 claims description 2
• CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 2
• BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 claims description 2
• BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 claims description 2
• 229960004833 dexamethasone phosphate Drugs 0.000 claims description 2
• VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 claims description 2
• 229960004511 fludroxycortide Drugs 0.000 claims description 2
• 229960000676 flunisolide Drugs 0.000 claims description 2
• 229960000289 fluticasone propionate Drugs 0.000 claims description 2
• WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 2
• 229960001524 hydrocortisone butyrate Drugs 0.000 claims description 2
• 229950000785 hydrocortisone phosphate Drugs 0.000 claims description 2
• 229960001680 ibuprofen Drugs 0.000 claims description 2
• 229960000905 indomethacin Drugs 0.000 claims description 2
• 239000011777 magnesium Substances 0.000 claims description 2
• 229910052749 magnesium Inorganic materials 0.000 claims description 2
• 229940091250 magnesium supplement Drugs 0.000 claims description 2
• 229960001293 methylprednisolone acetate Drugs 0.000 claims description 2
• 229960004123 mometasone furoate monohydrate Drugs 0.000 claims description 2
• 229960002009 naproxen Drugs 0.000 claims description 2
• RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 2
• 229960004398 nedocromil Drugs 0.000 claims description 2
• 229960001639 penicillamine Drugs 0.000 claims description 2
• MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
• 229960000371 rofecoxib Drugs 0.000 claims description 2
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 2
• 229960001940 sulfasalazine Drugs 0.000 claims description 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 2
• 229960000894 sulindac Drugs 0.000 claims description 2
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical group CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
• 229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
• YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
• 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
• KYLIMUJRJDIPPF-UHFFFAOYSA-N trisalicylate Chemical compound O=C1OC2=CC=CC=C2C(=O)OC2=CC=CC=C2C(=O)OC2=CC=CC=C12 KYLIMUJRJDIPPF-UHFFFAOYSA-N 0.000 claims description 2
• 229960002004 valdecoxib Drugs 0.000 claims description 2
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims description 2
• 108010002352 Interleukin-1 Proteins 0.000 claims 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
• 125000003827 glycol group Chemical group 0.000 claims 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
• PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 claims 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
• 150000003871 sulfonates Chemical class 0.000 abstract description 4
• 229940088597 hormone Drugs 0.000 abstract description 2
• 239000005556 hormone Substances 0.000 abstract description 2
• 150000003431 steroids Chemical class 0.000 abstract 1
• 210000004027 cell Anatomy 0.000 description 107
• 230000000694 effects Effects 0.000 description 74
• 230000000770 proinflammatory effect Effects 0.000 description 57
• 239000002158 endotoxin Substances 0.000 description 55
• 229920006008 lipopolysaccharide Polymers 0.000 description 55
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 45
• 230000028327 secretion Effects 0.000 description 45
• QNOCRUSVMMAKSC-CCEZHUSRSA-N (3e)-1-methyl-3-(2-oxo-1h-indol-3-ylidene)indol-2-one Chemical compound C12=CC=CC=C2N(C)C(=O)\C1=C\1C2=CC=CC=C2NC/1=O QNOCRUSVMMAKSC-CCEZHUSRSA-N 0.000 description 41
• 241000699670 Mus sp. Species 0.000 description 33
• 201000004681 Psoriasis Diseases 0.000 description 33
• 206010009900 Colitis ulcerative Diseases 0.000 description 32
• 230000003110 anti-inflammatory effect Effects 0.000 description 32
• 229940079593 drug Drugs 0.000 description 29
• 230000004054 inflammatory process Effects 0.000 description 27
• 206010039073 rheumatoid arthritis Diseases 0.000 description 27
• 208000024891 symptom Diseases 0.000 description 26
• 206010061218 Inflammation Diseases 0.000 description 25
• 108090000623 proteins and genes Proteins 0.000 description 24
• 108091007914 CDKs Proteins 0.000 description 23
• 201000006704 Ulcerative Colitis Diseases 0.000 description 23
• 239000000463 material Substances 0.000 description 22
• 210000001072 colon Anatomy 0.000 description 21
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 20
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 20
• 230000001684 chronic effect Effects 0.000 description 20
• 238000013518 transcription Methods 0.000 description 20
• 230000035897 transcription Effects 0.000 description 20
• CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical class N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 19
• 230000005764 inhibitory process Effects 0.000 description 19
• 201000006417 multiple sclerosis Diseases 0.000 description 19
• 235000018102 proteins Nutrition 0.000 description 19
• 102000004169 proteins and genes Human genes 0.000 description 19
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 18
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 17
• 108700012920 TNF Proteins 0.000 description 17
• 230000006378 damage Effects 0.000 description 17
• 229960000485 methotrexate Drugs 0.000 description 17
• 230000001225 therapeutic effect Effects 0.000 description 17
• 150000003384 small molecules Chemical class 0.000 description 16
• 239000002609 medium Substances 0.000 description 15
• 238000003753 real-time PCR Methods 0.000 description 15
• 230000000638 stimulation Effects 0.000 description 15
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
• 208000024827 Alzheimer disease Diseases 0.000 description 14
• 230000001965 increasing effect Effects 0.000 description 14
• 230000033228 biological regulation Effects 0.000 description 13
• 239000003112 inhibitor Substances 0.000 description 13
• 230000001105 regulatory effect Effects 0.000 description 13
• 208000011231 Crohn disease Diseases 0.000 description 12
• 206010022489 Insulin Resistance Diseases 0.000 description 12
• 230000007423 decrease Effects 0.000 description 12
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
• 239000000725 suspension Substances 0.000 description 12
• 238000012360 testing method Methods 0.000 description 12
• 239000003981 vehicle Substances 0.000 description 12
• 238000002965 ELISA Methods 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• 208000037976 chronic inflammation Diseases 0.000 description 11
• 239000013641 positive control Substances 0.000 description 11
• 206010012735 Diarrhoea Diseases 0.000 description 10
• 108010008165 Etanercept Proteins 0.000 description 10
• 210000001744 T-lymphocyte Anatomy 0.000 description 10
• 238000003556 assay Methods 0.000 description 10
• 230000007246 mechanism Effects 0.000 description 10
• 230000035755 proliferation Effects 0.000 description 10
• 230000009467 reduction Effects 0.000 description 10
• 210000001519 tissue Anatomy 0.000 description 10
• 235000000177 Indigofera tinctoria Nutrition 0.000 description 9
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 9
• 208000018737 Parkinson disease Diseases 0.000 description 9
• 230000004913 activation Effects 0.000 description 9
• 238000010171 animal model Methods 0.000 description 9
• 230000037396 body weight Effects 0.000 description 9
• 230000006020 chronic inflammation Effects 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 239000003102 growth factor Substances 0.000 description 9
• 229940097275 indigo Drugs 0.000 description 9
• COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 9
• 230000006698 induction Effects 0.000 description 9
• 208000015122 neurodegenerative disease Diseases 0.000 description 9
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
• 208000023275 Autoimmune disease Diseases 0.000 description 8
• CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 8
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
• 208000037273 Pathologic Processes Diseases 0.000 description 8
• 235000001014 amino acid Nutrition 0.000 description 8
• 229940024606 amino acid Drugs 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 239000003651 drinking water Substances 0.000 description 8
• 235000020188 drinking water Nutrition 0.000 description 8
• 210000000981 epithelium Anatomy 0.000 description 8
• 208000015181 infectious disease Diseases 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 8
• 239000010410 layer Substances 0.000 description 8
• 108020004999 messenger RNA Proteins 0.000 description 8
• 230000001575 pathological effect Effects 0.000 description 8
• 230000009054 pathological process Effects 0.000 description 8
• 102000019034 Chemokines Human genes 0.000 description 7
• 108010012236 Chemokines Proteins 0.000 description 7
• 206010017912 Gastroenteritis radiation Diseases 0.000 description 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
• 208000032843 Hemorrhage Diseases 0.000 description 7
• 108090001007 Interleukin-8 Proteins 0.000 description 7
• 102000004890 Interleukin-8 Human genes 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 210000004556 brain Anatomy 0.000 description 7
• 230000003628 erosive effect Effects 0.000 description 7
• 235000003599 food sweetener Nutrition 0.000 description 7
• 230000008595 infiltration Effects 0.000 description 7
• 238000001764 infiltration Methods 0.000 description 7
• 210000004969 inflammatory cell Anatomy 0.000 description 7
• 210000004877 mucosa Anatomy 0.000 description 7
• 230000008506 pathogenesis Effects 0.000 description 7
• 208000020624 radiation proctitis Diseases 0.000 description 7
• 239000003765 sweetening agent Substances 0.000 description 7
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
• 206010007559 Cardiac failure congestive Diseases 0.000 description 6
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 206010016654 Fibrosis Diseases 0.000 description 6
• 206010019280 Heart failures Diseases 0.000 description 6
• 102000004877 Insulin Human genes 0.000 description 6
• 108090001061 Insulin Proteins 0.000 description 6
• 241000581650 Ivesia Species 0.000 description 6
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
• 238000000692 Student's t-test Methods 0.000 description 6
• 210000000577 adipose tissue Anatomy 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 206010003246 arthritis Diseases 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 230000024245 cell differentiation Effects 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 229940073621 enbrel Drugs 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 239000008103 glucose Substances 0.000 description 6
• 210000000987 immune system Anatomy 0.000 description 6
• 229940125396 insulin Drugs 0.000 description 6
• 230000007774 longterm Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 229920000609 methyl cellulose Polymers 0.000 description 6
• 235000010981 methylcellulose Nutrition 0.000 description 6
• 239000001923 methylcellulose Substances 0.000 description 6
• 210000001616 monocyte Anatomy 0.000 description 6
• 239000013642 negative control Substances 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 239000003755 preservative agent Substances 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 238000001959 radiotherapy Methods 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 230000014616 translation Effects 0.000 description 6
• 208000024172 Cardiovascular disease Diseases 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 5
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 5
• 208000008589 Obesity Diseases 0.000 description 5
• 241000283984 Rodentia Species 0.000 description 5
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
• 210000001789 adipocyte Anatomy 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 208000034158 bleeding Diseases 0.000 description 5
• 230000000740 bleeding effect Effects 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 239000007859 condensation product Substances 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 239000002988 disease modifying antirheumatic drug Substances 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 239000012153 distilled water Substances 0.000 description 5
• 201000002491 encephalomyelitis Diseases 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 230000004761 fibrosis Effects 0.000 description 5
• 238000009541 flexible sigmoidoscopy Methods 0.000 description 5
• 235000013305 food Nutrition 0.000 description 5
• 239000003018 immunosuppressive agent Substances 0.000 description 5
• 229940125721 immunosuppressive agent Drugs 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000003902 lesion Effects 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 230000000394 mitotic effect Effects 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 235000020824 obesity Nutrition 0.000 description 5
• 239000012188 paraffin wax Substances 0.000 description 5
• 230000036961 partial effect Effects 0.000 description 5
• 238000011084 recovery Methods 0.000 description 5
• 210000000664 rectum Anatomy 0.000 description 5
• 229940116176 remicade Drugs 0.000 description 5
• 238000010186 staining Methods 0.000 description 5
• 230000001629 suppression Effects 0.000 description 5
• 208000004998 Abdominal Pain Diseases 0.000 description 4
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
• 108010057466 NF-kappa B Proteins 0.000 description 4
• 102000003945 NF-kappa B Human genes 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 208000025865 Ulcer Diseases 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 208000007502 anemia Diseases 0.000 description 4
• 239000007900 aqueous suspension Substances 0.000 description 4
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 238000004364 calculation method Methods 0.000 description 4
• 229910052799 carbon Inorganic materials 0.000 description 4
• 235000014113 dietary fatty acids Nutrition 0.000 description 4
• 239000002270 dispersing agent Substances 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 210000001339 epidermal cell Anatomy 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 229960000403 etanercept Drugs 0.000 description 4
• 229930195729 fatty acid Natural products 0.000 description 4
• 239000000194 fatty acid Substances 0.000 description 4
• 150000004665 fatty acids Chemical class 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• 239000003906 humectant Substances 0.000 description 4
• 229940048921 humira Drugs 0.000 description 4
• 229940054136 kineret Drugs 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 210000000440 neutrophil Anatomy 0.000 description 4
• 230000000144 pharmacologic effect Effects 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000005855 radiation Effects 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 230000037390 scarring Effects 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 238000007619 statistical method Methods 0.000 description 4
• 229960004793 sucrose Drugs 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• 230000035899 viability Effects 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• 108010055166 Chemokine CCL5 Proteins 0.000 description 3
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 3
• 201000004624 Dermatitis Diseases 0.000 description 3
• 208000001640 Fibromyalgia Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 206010020649 Hyperkeratosis Diseases 0.000 description 3
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
• 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 3
• 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 3
• 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 3
• 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 3
• 102000006386 Myelin Proteins Human genes 0.000 description 3
• 108010083674 Myelin Proteins Proteins 0.000 description 3
• 206010030113 Oedema Diseases 0.000 description 3
• 208000002193 Pain Diseases 0.000 description 3
• 208000031481 Pathologic Constriction Diseases 0.000 description 3
• 235000019483 Peanut oil Nutrition 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
• 235000010489 acacia gum Nutrition 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 229960002964 adalimumab Drugs 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 239000000460 chlorine Substances 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 239000003246 corticosteroid Substances 0.000 description 3
• 229960001334 corticosteroids Drugs 0.000 description 3
• 238000005520 cutting process Methods 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 229960000633 dextran sulfate Drugs 0.000 description 3
• 230000009266 disease activity Effects 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 229940011871 estrogen Drugs 0.000 description 3
• 239000000262 estrogen Substances 0.000 description 3
• 235000019441 ethanol Nutrition 0.000 description 3
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 210000003630 histaminocyte Anatomy 0.000 description 3
• 201000001421 hyperglycemia Diseases 0.000 description 3
• 206010020718 hyperplasia Diseases 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 229960000598 infliximab Drugs 0.000 description 3
• 230000000968 intestinal effect Effects 0.000 description 3
• 210000001503 joint Anatomy 0.000 description 3
• 229940057995 liquid paraffin Drugs 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 238000002483 medication Methods 0.000 description 3
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
• 239000002480 mineral oil Substances 0.000 description 3
• 235000010446 mineral oil Nutrition 0.000 description 3
• 210000005012 myelin Anatomy 0.000 description 3
• 239000004006 olive oil Substances 0.000 description 3
• 235000008390 olive oil Nutrition 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 239000005022 packaging material Substances 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 231100000915 pathological change Toxicity 0.000 description 3
• 230000036285 pathological change Effects 0.000 description 3
• 239000000312 peanut oil Substances 0.000 description 3
• 230000036262 stenosis Effects 0.000 description 3
• 208000037804 stenosis Diseases 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 235000015112 vegetable and seed oil Nutrition 0.000 description 3
• 239000008158 vegetable oil Substances 0.000 description 3
• WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• MLCPSWPIYHDOKG-BUHFOSPRSA-N (3e)-3-(2-oxo-1h-indol-3-ylidene)-1h-indol-2-one Chemical compound O=C\1NC2=CC=CC=C2C/1=C1/C2=CC=CC=C2NC1=O MLCPSWPIYHDOKG-BUHFOSPRSA-N 0.000 description 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 208000037259 Amyloid Plaque Diseases 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 208000020084 Bone disease Diseases 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
• 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 208000002881 Colic Diseases 0.000 description 2
• 108010058546 Cyclin D1 Proteins 0.000 description 2
• 208000009386 Experimental Arthritis Diseases 0.000 description 2
• 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
• 208000018522 Gastrointestinal disease Diseases 0.000 description 2
• 102100023541 Glutathione S-transferase omega-1 Human genes 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 108010033040 Histones Proteins 0.000 description 2
• 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
• 101000906386 Homo sapiens Glutathione S-transferase omega-1 Proteins 0.000 description 2
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 102000009433 Insulin Receptor Substrate Proteins Human genes 0.000 description 2
• 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 2
• 102100025390 Integrin beta-2 Human genes 0.000 description 2
• 102100037850 Interferon gamma Human genes 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• 238000012449 Kunming mouse Methods 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
• 229940124150 Lymphocyte inhibitor Drugs 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
• 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 206010033645 Pancreatitis Diseases 0.000 description 2
• 208000003251 Pruritus Diseases 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 238000011530 RNeasy Mini Kit Methods 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 206010044565 Tremor Diseases 0.000 description 2
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 206010000269 abscess Diseases 0.000 description 2
• 239000000205 acacia gum Substances 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 229960002459 alefacept Drugs 0.000 description 2
• 125000002877 alkyl aryl group Chemical group 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 210000001765 aortic valve Anatomy 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 125000003710 aryl alkyl group Chemical group 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 230000003305 autocrine Effects 0.000 description 2
• 229960002170 azathioprine Drugs 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 229940072225 canasa Drugs 0.000 description 2
• 239000013553 cell monolayer Substances 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
• 238000002052 colonoscopy Methods 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 230000035622 drinking Effects 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
• 230000005713 exacerbation Effects 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 210000003608 fece Anatomy 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 210000000224 granular leucocyte Anatomy 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000035876 healing Effects 0.000 description 2
• 230000003862 health status Effects 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 239000003701 inert diluent Substances 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 239000012948 isocyanate Substances 0.000 description 2
• 150000002513 isocyanates Chemical class 0.000 description 2
• 230000007803 itching Effects 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 210000003127 knee Anatomy 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 210000002429 large intestine Anatomy 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 208000019423 liver disease Diseases 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 210000005004 lymphoid follicle Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 230000011278 mitosis Effects 0.000 description 2
• 239000003607 modifier Substances 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 230000003959 neuroinflammation Effects 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 239000012053 oil suspension Substances 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 230000003076 paracrine Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
• 210000001258 synovial membrane Anatomy 0.000 description 2
• 239000008399 tap water Substances 0.000 description 2
• 235000020679 tap water Nutrition 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
• 210000003932 urinary bladder Anatomy 0.000 description 2
• 230000008728 vascular permeability Effects 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 208000016261 weight loss Diseases 0.000 description 2
• 230000004580 weight loss Effects 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• YREOLPGEVLLKMB-UHFFFAOYSA-N 3-methylpyridin-1-ium-2-amine bromide hydrate Chemical compound O.[Br-].Cc1ccc[nH+]c1N YREOLPGEVLLKMB-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 208000007788 Acute Liver Failure Diseases 0.000 description 1
• 206010048998 Acute phase reaction Diseases 0.000 description 1
• 108010076365 Adiponectin Proteins 0.000 description 1
• 102000011690 Adiponectin Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 241001482106 Alosa Species 0.000 description 1
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 101710145634 Antigen 1 Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 208000034309 Bacterial disease carrier Diseases 0.000 description 1
• GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 108010084313 CD58 Antigens Proteins 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
• 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 206010063094 Cerebral malaria Diseases 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
• ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 238000005698 Diels-Alder reaction Methods 0.000 description 1
• RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
• 208000005189 Embolism Diseases 0.000 description 1
• 208000002087 Endarteritis Diseases 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 208000034347 Faecal incontinence Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102100030948 Glutathione S-transferase omega-2 Human genes 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010001483 Glycogen Synthase Proteins 0.000 description 1
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 101001010149 Homo sapiens Glutathione S-transferase omega-2 Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
• 208000004044 Hypesthesia Diseases 0.000 description 1
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 238000012404 In vitro experiment Methods 0.000 description 1
• 102000003746 Insulin Receptor Human genes 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
• 206010023203 Joint destruction Diseases 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 108010063045 Lactoferrin Proteins 0.000 description 1
• 102100032241 Lactotransferrin Human genes 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 206010067125 Liver injury Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 102000043131 MHC class II family Human genes 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• 208000034819 Mobility Limitation Diseases 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 206010028124 Mucosal ulceration Diseases 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 102000004140 Oncostatin M Human genes 0.000 description 1
• 108090000630 Oncostatin M Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 108010016731 PPAR gamma Proteins 0.000 description 1
• 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
• 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 206010036772 Proctalgia Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 206010037575 Pustular psoriasis Diseases 0.000 description 1
• 206010057071 Rectal tenesmus Diseases 0.000 description 1
• 108010047909 Resistin Proteins 0.000 description 1
• 102000007156 Resistin Human genes 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 230000004658 acute-phase response Effects 0.000 description 1
• 230000003919 adipocyte function Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 150000004705 aldimines Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 125000003342 alkenyl group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000003698 anagen phase Effects 0.000 description 1
• 229960004238 anakinra Drugs 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 230000003092 anti-cytokine Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 238000011861 anti-inflammatory therapy Methods 0.000 description 1
• 230000001857 anti-mycotic effect Effects 0.000 description 1
• 239000003793 antidiarrheal agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 229940030999 antipsoriatics Drugs 0.000 description 1
• 210000000436 anus Anatomy 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009697 arginine Nutrition 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 210000001188 articular cartilage Anatomy 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000006470 autoimmune attack Effects 0.000 description 1
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000008355 cartilage degradation Effects 0.000 description 1
• 101150073031 cdk2 gene Proteins 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 231100000762 chronic effect Toxicity 0.000 description 1
• 230000008576 chronic process Effects 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 229940121657 clinical drug Drugs 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 208000026758 coronary atherosclerosis Diseases 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 150000001993 dienes Chemical class 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 208000010643 digestive system disease Diseases 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 238000011979 disease modifying therapy Methods 0.000 description 1
• 208000016097 disease of metabolism Diseases 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 229960000284 efalizumab Drugs 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 230000036566 epidermal hyperplasia Effects 0.000 description 1
• 230000004890 epithelial barrier function Effects 0.000 description 1
• 125000003700 epoxy group Chemical group 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000011536 extraction buffer Substances 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 230000002550 fecal effect Effects 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000021588 free fatty acids Nutrition 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 208000018685 gastrointestinal system disease Diseases 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000004554 glutamine Nutrition 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical group 0.000 description 1
• 208000010758 granulomatous inflammation Diseases 0.000 description 1
• 239000003966 growth inhibitor Substances 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 208000035861 hematochezia Diseases 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 231100000234 hepatic damage Toxicity 0.000 description 1
• 241000411851 herbal medicine Species 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 208000034783 hypoesthesia Diseases 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000007233 immunological mechanism Effects 0.000 description 1
• 239000012133 immunoprecipitate Substances 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000018276 interleukin-1 production Effects 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 150000004658 ketimines Chemical class 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 238000000021 kinase assay Methods 0.000 description 1
• TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
• 229940078795 lactoferrin Drugs 0.000 description 1
• 235000021242 lactoferrin Nutrition 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 230000004130 lipolysis Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 230000008818 liver damage Effects 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 229960005015 local anesthetics Drugs 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 238000012153 long-term therapy Methods 0.000 description 1
• 208000018769 loss of vision Diseases 0.000 description 1
• 231100000864 loss of vision Toxicity 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• 210000000274 microglia Anatomy 0.000 description 1
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
• 229920001206 natural gum Polymers 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 210000000885 nephron Anatomy 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 238000002559 palpation Methods 0.000 description 1
• 230000009745 pathological pathway Effects 0.000 description 1
• 230000035778 pathophysiological process Effects 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 238000011458 pharmacological treatment Methods 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 238000001126 phototherapy Methods 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 230000001144 postural effect Effects 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000010944 pre-mature reactiony Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 206010036784 proctocolitis Diseases 0.000 description 1
• 208000017048 proctosigmoiditis Diseases 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000000751 protein extraction Methods 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 238000003345 scintillation counting Methods 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 210000001599 sigmoid colon Anatomy 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 102000035025 signaling receptors Human genes 0.000 description 1
• 108091005475 signaling receptors Proteins 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 210000004085 squamous epithelial cell Anatomy 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 238000011476 stem cell transplantation Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 210000002437 synoviocyte Anatomy 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 208000012271 tenesmus Diseases 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 229940126680 traditional chinese medicines Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 230000006433 tumor necrosis factor production Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 230000036269 ulceration Effects 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 230000004393 visual impairment Effects 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1